ProteinQure is a technology company.
ProteinQure is a clinical-stage biotech company focused on the design of novel exotic peptides with broad therapeutic applications, leveraging AI for peptide-drug conjugate development.
ProteinQure has raised $4.5M across 2 funding rounds.
ProteinQure has raised $4.5M in total across 2 funding rounds.
ProteinQure is a clinical-stage biotechnology company that develops AI-driven computational platforms to design novel peptide-based therapeutics with precise tissue- and cell-specific delivery. Their proprietary platform, ProteinStudio™, integrates quantum computing, machine learning, and molecular simulations to design exotic peptides incorporating thousands of non-natural amino acids, enabling the creation of peptide-drug conjugates that target previously inaccessible biological targets. ProteinQure’s lead candidate, PQ203, is a first-in-class AI-designed peptide-drug conjugate currently in Phase 1 clinical trials for advanced solid tumors, including triple-negative breast cancer, demonstrating significant growth momentum and clinical validation of their technology[1][2][3].
Founded in 2017 by a multidisciplinary team including Tomas Babej, Mark Fingerhuth, Christopher Ing, and Lucas Siow, ProteinQure emerged from the Creative Destruction Lab’s Quantum stream at the University of Toronto. The founders combined expertise in quantum physics, computational biology, and machine learning to address the challenge of designing protein-based drugs, which involves navigating an astronomically large chemical space. Early mentorship and funding from angel investors and industry advisors helped the company evolve from a computational infrastructure startup to a clinical-stage biotech firm, marking a milestone as one of the first AI drug discovery companies from the Canadian deep-tech ecosystem to reach human clinical trials[4][5].
ProteinQure rides the convergence of AI, quantum computing, and computational biology, a transformative trend in drug discovery aimed at reducing costs and timelines while expanding the druggable proteome. The timing is critical as traditional drug development faces high attrition and expense, and AI-powered platforms offer scalable, predictive design capabilities. ProteinQure’s success exemplifies how deep-tech startups can leverage emerging quantum and machine learning technologies to impact precision medicine, influencing both biotech innovation and pharmaceutical R&D paradigms[1][4][5].
ProteinQure is poised to expand its clinical pipeline beyond oncology into neurology, nephrology, and rare diseases by leveraging its platform’s versatility in designing peptides for diverse payloads, including cytotoxics, radioisotopes, and oligonucleotides. Future trends shaping their journey include advances in quantum hardware, AI model sophistication, and growing demand for targeted biologics. As ProteinQure continues clinical validation and partnership development, it may become a leading example of AI-driven peptide therapeutics, potentially reshaping drug discovery and delivery with precision-designed biologics[2][3][5][8].
ProteinQure has raised $4.5M in total across 2 funding rounds.
ProteinQure's investors include 7 Gate Ventures, Accel, Chloe Sladden, Caffeinated Capital, CRV, Electric Capital, First Round Capital, FPV Fund, General Catalyst, Hex Capital, Susa Ventures, Third Kind Ventures.
ProteinQure has raised $4.5M across 2 funding rounds. Most recently, it raised $4.0M Seed in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2019 | $4.0M Seed | 7 Gate Ventures, Accel, Chloe Sladden, Caffeinated Capital, CRV, Electric Capital, First Round Capital, FPV Fund, General Catalyst, Hex Capital, Susa Ventures, Third Kind Ventures, Greg Brockman, Sam Altman | |
| Jun 1, 2018 | $540K Seed | 7 Gate Ventures, Accel, CRV, Hex Capital, Third Kind Ventures |